$Cabaletta Bio (CABA.US)$
“Title: Clinical and Translational Studies of Rese-cel (an anti-CD19 CAR T Therapy) in Myositis, SLE, and Systemic Sclerosis: RESET Phase I/II Trials
Date and Time: Saturday, February 22, 2025, 10:15 a.m. – 10:30 a.m. CET
*Additional information can be accessed on the website of each scientific meeting. Presentation materials will be made available on the Posters & Publications section of the Company's website following each event.
About rese-cel (formerly referred to ...

$Cabaletta Bio (CABA.US)$
The latest clinical data from Cabaletta Bio's rese-cel program represents a significant milestone in autoimmune disease treatment. The achievement of DORIS remission in 3 out of 4 SLE patients, complete renal response in lupus nephritis, and sustained improvement in dermatomyositis - all while discontinuing immunosuppressants - suggests a potentially transformative therapeutic approach.
The confirmed deep B cell depletion, both in circulation and ...

$Cabaletta Bio (CABA.US)$
Breakthrough Clinical Results: Rese-cel Treatment Achieves Remission in Lupus Patients, Shows Promise Across Autoimmune Disorders

$Cabaletta Bio (CABA.US)$
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications

$Cabaletta Bio (CABA.US)$ Reuters· 5 mins ago
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings

$Cabaletta Bio (CABA.US)$
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
Tuesday, 18th February at 7:00 am
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these patients discontinued all immunosu...

$Cabaletta Bio (CABA.US)$ hold?

$CABA 241220 2.50P$ looks like XMAS in here

$CABA 241220 2.50P$ what this Company do, they got some news yet?